Adherex Technologies Inc. (TSX:AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that it has initiated a clinical proof-of-mechanism trial of eniluracil. This study, which will be conducted at the University of Alabama at Birmingham, is expected to involve up to 20 patients and provide Adherex with human data on the effects of low doses of eniluracil in tumor tissue. Adherex is developing eniluracil to improve the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most commonly used anti-cancer drugs.
